Table 1 Clinical characteristics of attacks requiring orotracheal intubation versus attacks not requiring orotracheal intubation

Gender: female/male

64 (87.7)

7 (87.5)

57 (87.7)

0.925

Place of birth

–

 France—metropolitan area

34 (46.6)

1 (12.5)

33 (50.8)

 France–West indies–Guyana

6 (8.2)

4 (50.0)

2 (3.1)

 Asia

6 (8.2)

0 (0.0)

6 (9.2)

 North Africa

6 (8.2)

0 (0.0)

6 (9.2)

 Sub-Saharan Africa

20 (27.4)

2 (25.0)

18 (27.7)

 Middle East

1 (1.4)

1 (12.5)

0 (0.0)

Age at start of the disease, years, median (IQR)

33.20 [21.30, 46.90]

47.15 [33.18, 55.70]

32.90 [19.60, 43.40]

0.662

Age at attack onset, years

43 (31–53)

50 (42–56)

43 (28–53)

0.834

First attack of NMOSD-AQP4 disease

22 (30.1)

4 (50)

18 (27.7)

0.592

Attack occurring in the first 6 months of NMOSD-AQP4 disease

28 (38.9)

7 (87.5)

21 (32.8)

0.411

Any active NMOSD disease modifying therapy (DMT)^a

36 (49.3)

0 (0)

36 (55.4)

–

Type of DMT

 Azathioprine

8 (11)

–

8 (12.3)

 Mycophenolate mofetil

11 (15.1)

–

11 (16.9)

 Rituximab

8 (11)

–

8 (12.3)

 Cyclophosphamide

3 (4.1)

–

3 (4.6)

 Methotrexate

4 (5.5)

–

4 (6.2)

 TPE

6 (8.2)

–

6 (9.2)

EDSS before attack

2.0 (0–3.5)

1.0 (0–3.5)

2.0 (0–3.5)

0.460

Modified Rankin scale before attack

1 (0–2)

0.5 (0–3.25)

1 (0–2)

0.380

Clinical examination at the hospital entry

 EDSS at admission

6.0 (3.5–8)

7.5 (6.0–8.5)

6.0 (3.5–8)

0.029

 Lower limb paresis

46 (63)

6 (75)

40 (61.5)

0.460

 Upper limb paresis

25 (34.2)

6 (75)

19 (29.2)

0.366

 Dyspnea (number of patients with available data)

7 (9.7) (71)

3 (50) (6)

4 (6.6) (65)

0.002